PHARMARON (03759) has projected its first-half 2025 financial performance, anticipating revenue between 6.333 billion and 6.501 billion yuan – marking a robust 13% to 16% year-on-year expansion. However, the pharmaceutical research giant flagged a sharp decline in shareholder returns, with net profit attributable to owners expected to plummet 36%-39% to approximately 679 million-713 million yuan.
Contrasting this downturn, the company's non-recurring net profit (excluding extraordinary items) demonstrated remarkable resilience, soaring 34%-39% to reach 624 million-648 million yuan. Meanwhile, adjusted non-IFRS net profit attributable to shareholders climbed moderately by 6%-11%.
Midpoint analysis of the forecast reveals stronger second-quarter momentum: Q2 revenue growth accelerated to 13.11% YoY. Crucially, non-recurring net profit surged 23.33% during the quarter, while adjusted non-IFRS net profit attributable to shareholders jumped 13.67%.
Management attributed the shareholder profit contraction primarily to diminished non-recurring gains, emphasizing that core operations maintained healthy progress throughout the period. This divergence highlights how transient financial impacts overshadowed otherwise solid underlying business performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.